Efficacy and safety of repeated intrathecal triamcinolone acetonide application in progressive multiple sclerosis patients

Journal of the Neurological Sciences

Volumn 211, Issue 1-2, 2003, Pages 81-84

  Hoffmann, Volker ^a   Schimrigk, Sebastian ^a   Islamova, Saida ^a   Hellwig, Kerstin ^a   Lukas, Carsten ^a   Brune, Nils ^a   Pöhlau, Dieter ^a   Przuntek, Horst ^a   Müller, Thomas ^a  

^a ST JOSEF HOSPITAL   (Germany)

Author keywords

Efficacy; Intrathecal; Progressive multiple sclerosis; Triamcinolone acetonide

Indexed keywords

TRIAMCINOLONE ACETONIDE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DISEASE SEVERITY; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; FEMALE; FOLLOW UP; FRACTURE; HEADACHE; HUMAN; LEG PAIN; MALE; MULTIPLE SCLEROSIS; OVARY CANCER; PRIORITY JOURNAL; SUSTAINED RELEASE PREPARATION; TINNITUS; TREATMENT OUTCOME; WALKING;

EID: 0037953010     PISSN: 0022510X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-510X(03)00060-1     Document Type: Article

References (11)

1. Goodin D.S., Frohman E.M., Garmany G.P. Jr., Halper J., Likosky W.H., Lublin F.D.et al. Disease modifying therapies in multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines. Neurology. 58(2):2002;169-178.
2. Rohrbach E., Kappos L., Städt D., Kaiser D., Hennes A., Dommasch D.et al. Intrathecal versus oral corticosteroid therapy of spinal symptoms in multiple sclerosis: a double-blind controlled trial. Neurology. 38(Suppl. 1):1988;256.
3. Heun R., Sliwka U., Ruttinger H., Schimrigk K. Intrathecal versus systemic corticosteroids in the treatment of multiple sclerosis: results of a pilot study. J. Neurol. 239(1):1992;31-35.
4. Nelson D.A., Landau W.M. Intraspinal steroids: history, efficacy, accidentality, and controversy with review of United States Food and Drug Administration reports. J. Neurol. Neurosurg. Psychiatry. 70(4):2001;433-443.
5. Kotani N., Kushikata T., Hashimoto H., Kimura F., Muraoka M., Yodono M.et al. Intrathecal methylprednisolone for intractable postherpetic neuralgia. N. Engl. J. Med. 343(21):2000;1514-1519.
6. Poser C.M., Paty D.W., Scheinberg L., McDonald W.I., Davis F.A., Ebers G.C.et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann. Neurol. 13(3):1983;227-231.
7. Braune H.J., Huffmann G.A. A prospective double-blind clinical trial, comparing the sharp Quincke needle (22G) with an "atraumatic" needle (22G) in the induction of post-lumbar puncture headache. Acta Neurol. Scand. 86(1):1992;50-54.
8. Kurtzke J.F. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology. 33(11):1983;1444-1452.
9. Neu I., Reusche E., Rodiek S. Endogenous cortisol levels after intrathecal injection of triamicinolone acetonide in patients with neurological disease. Dtsch. Med. Wochenschr. 103(35):1978;1368-1370. [author's transl].
10. Goodkin D.E., Kinkel R.P., Weinstock-Guttman B., VanderBrug-Medendorp S., Secic M., Gogol D.et al. A phase II study of i.v. methylprednisolone in secondary-progressive multiple sclerosis. Neurology. 51(1):1998;239-245.
11. Zivadinov R., Rudick R.A., De Masi R., Nasuelli D., Ukmar M., Pozzi-Mucelli R.S.et al. Effects of IV methylprednisolone on brain atrophy in relapsing-remitting MS. Neurology. 57(7):2001;1239-1247.